<DOC>
	<DOCNO>NCT02486796</DOCNO>
	<brief_summary>This study examine effect addition naturopathic immunologic and/or inflammatory parameter and/or quality life woman receive neoadjuvant chemotherapy breast cancer .</brief_summary>
	<brief_title>Immediate Delayed Naturopathic Medicine Combination With Neo-Adjuvant Chemotherapy Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Melatonin</mesh_term>
	<mesh_term>Coenzyme Q10</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>Female 18 year old Eastern Cooperative Oncology Group ( ECOG ) performance status ≤1 Biopsy proven diagnosis invasive adenocarcinoma breast Recommendation neoadjuvant chemotherapy . Left Ventricular Ejection Fraction ( LVEF ) assessment multigated acquisition scan echocardiogram within 3 month enter study Blood count : Absolute Neutrophil Count ≥1200 cells/mm^3 Platelet count ≥100,000/mm^3 Hemoglobin ≥10g/dL Serum creatinine ≤ Upper Limit Normal ( ULN ) laboratory range Total bilirubin ≤ ULN laboratory range , unless patient elevation &gt; ULN 1.5 time ULN result Gilbert 's disease similar syndrome Alkaline phosphatase less equal 2.5 x ULN ; Aspartate aminotransferase ( AST ) less equal 1.5 x ULN laboratory range If skeletal pain present alkaline phosphatase &gt; ULN ( less equal 2.5x ULN ) , bone scan Positron Emission Tomography ( PET ) scan must demonstrate metastatic disease AST alkaline phosphatase great ULN , metastatic disease liver identify CT , MRI PET scan Able swallow oral medication Willing forego naturopathic treatment first 2 treatment cycle Willing start continue naturopathic intervention prescribe Willing forego use nutritional botanical supplement study Stage 4 disease Present treatment Warfarin . Synchronous bilateral invasive breast cancer Treatment include radiation , chemotherapy , and/or target therapy currently diagnose breast cancer prior enter study Any sex hormonal therapy e.g . birth control , ovarian hormone replacement therapy , etc . participation study ) Continued therapy hormonal agent raloxifene , tamoxifen , selective estrogen receptor modulators Prior history breast cancer , include Ductal Carcinoma In Situ ( subject history Lobular Carcinoma In Situ eligible ) Prior therapy chemotherapy target therapy agent malignancy Cardiac disease would preclude use certain drug . This include confine : Active cardiac disease Angina pectoris require treatment Ventricular arrhythmia except control benign premature ventricular contraction Conduction abnormality require pacemaker Supraventricular nodal arrhythmia require pacemaker control medication Clinical significant valvular disease History cardiac disease Myocardial infarction Congestive heart failure Cardiomyopathy Uncontrolled hypertension , ( blood pressure 150/90 mm/Hg antihypertensive treatment ) History current symptomatic interstitial pneumonitis pulmonary fibrosis Sensory/motor neuropathy ≥ grade 2 Malabsorption syndrome , ulcerative colitis , resection stomach small bowel , disease significantly affect gastrointestinal function Other nonmalignant systemic disease preclude treatment study regimen require follow Contraindication corticosteroid Administration investigational agent within 30 day prior enter study . Administration therapeutic dos supplement study include maitake , melatonin Coenzyme Q10 previous 30 day . Administration therapeutic dos immune modulate botanical previous 30 day . Pregnancy lactation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>